Aroa Biosurgery (ASX:ARX) 3-Month Share Buyback Ratio: 0.00% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ARX Aroa Biosurgery Ltd ASX:ARX
60 GF Score
Price A$0.61
GF Value A$0.77
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery 3-Month Share Buyback Ratio?

Aroa Biosurgery ASX:ARX +8.93% 60 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 60/100 and a GF Value™ of A$0.77 (Modestly Undervalued). The stock has 1 warning sign investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

ASX:ARX
60GF Score
Aroa Biosurgery Ltd ASX:ARX
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Aroa Biosurgery (ASX:ARX) has a 3-Month Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's 3-Month Share Buyback Ratio too high?
Aroa Biosurgery's current 3-Month Share Buyback Ratio is 0.00. Overall, Aroa Biosurgery has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's 3-Month Share Buyback Ratio compare to ABT and SYK?
Aroa Biosurgery's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Aroa Biosurgery and its competitors. Aroa Biosurgery's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.77, compared to a current price of A$0.61 — trading 20.8% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Aroa Biosurgery's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.61 is trading 20.8% below its estimated GF Value™ of A$0.77. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: A$0.77 vs. price of A$0.61 (20.8% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
60GF Score

Get the complete analysis for ASX:ARX

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.61
Price
A$0.77
GF Value